What's Wrong With PepsiCo Stock?

PepsiCo shares have fallen 12% over five years and are down about 4% year-to-date in 2026, sharply underperforming the S&P 500's roughly 70% five-year gain and Coca-Cola's 55% rise. The article argues that investor concerns over GLP-1 appetite-suppression drugs hurting snack demand may be excessive, citing PepsiCo's still-sound fundamentals and nearly $100B in annual revenue. At 18x earnings, PepsiCo trades below Coca-Cola's 27x multiple and the S&P 500's 24x average, supporting a contrarian long-term value case.

Analysis

PEP's discount to KO is only actionable if the market is mispricing a temporary volume/mix headwind rather than a permanent impairment to the Frito-Lay franchise. The key distinction is elasticity: GLP-1 exposure is concentrated among a relatively narrow, higher-income patient cohort, while snacks are broadly distributed and supported by convenience-channel availability. More important near term, PEP has more scope than KO to restore earnings through SKU rationalization, pack-price architecture and productivity; that creates operating leverage if North American volumes merely stabilize rather than reaccelerate.

The risk is that the valuation gap correctly reflects structurally inferior execution, not an appetite-drug narrative. PEP's larger food mix carries greater exposure to private-label trade-down, input-cost volatility and retailer bargaining power, while KO's concentrate model is structurally more asset-light. Over the next 1-3 months, scanner-data trends in salty-snack volumes, promotional intensity and management commentary on elasticities matter more than broad GLP-1 prescription headlines; sustained negative volumes without offsetting mix would make an 18x multiple a value trap.

A relative-value setup is more compelling than an outright defensive-staples bet: PEP can outperform KO if earnings revisions stop falling and the valuation discount partially closes, even in a low-growth tape. The consensus may be over-attributing weak share performance to GLP-1s while underweighting cyclical self-help and the possibility that the GLP-1 concern has already compressed PEP's multiple. Conversely, any evidence of category-level household penetration declines rather than reduced consumption per user would validate a longer-duration impairment thesis.

Key Decisions for Investors

• Initiate a 3-6 month long PEP / short KO pair, dollar neutral, only after the next Nielsen/IRI read shows sequential stabilization in PEP salty-snack unit volumes. Target a 10-15% narrowing of the relative valuation discount; exit if PEP cuts organic-growth or EPS guidance, or if snack volumes remain materially negative for two consecutive reported quarters.
• For outright exposure, accumulate PEP in tranches ahead of the next earnings print rather than chase a narrative reversal. Underwrite a 12-month 15-20% total-return case from modest multiple normalization plus dividend, versus roughly 10% downside if earnings estimates reset; position size should remain modest until North America volume and gross-margin trends are verified.
• Do not use GLP-1 manufacturers as a direct hedge for PEP: demand linkage is too indirect and likely already reflected in obesity-drug valuations. Instead, monitor WMT and COST commentary on snack-category unit velocity and private-label share as the cleaner falsification signals.
• Set an alert for a widening PEP/KO relative-performance gap after earnings despite stable PEP guidance. That would indicate flows and technical de-risking rather than fundamentals, improving the entry point for the pair; a KO multiple de-rating driven by weaker beverage volumes is the principal risk to the short leg.